CN103732202A - 用于眼部给药的两部分制剂系统 - Google Patents

用于眼部给药的两部分制剂系统 Download PDF

Info

Publication number
CN103732202A
CN103732202A CN201280039854.XA CN201280039854A CN103732202A CN 103732202 A CN103732202 A CN 103732202A CN 201280039854 A CN201280039854 A CN 201280039854A CN 103732202 A CN103732202 A CN 103732202A
Authority
CN
China
Prior art keywords
listed
agent
therapeutic activity
buffer
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280039854.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·V·戈雷
S·尚卡
S·利基勒桑
C·P·普亚拉
S·尼尔万南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to CN201810562582.0A priority Critical patent/CN108514547A/zh
Publication of CN103732202A publication Critical patent/CN103732202A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280039854.XA 2011-07-26 2012-07-26 用于眼部给药的两部分制剂系统 Pending CN103732202A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810562582.0A CN108514547A (zh) 2011-07-26 2012-07-26 用于眼部给药的两部分制剂系统

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161511753P 2011-07-26 2011-07-26
US61/511,753 2011-07-26
PCT/US2012/048263 WO2013016494A1 (en) 2011-07-26 2012-07-26 Two part formulation system for ophthalmic delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810562582.0A Division CN108514547A (zh) 2011-07-26 2012-07-26 用于眼部给药的两部分制剂系统

Publications (1)

Publication Number Publication Date
CN103732202A true CN103732202A (zh) 2014-04-16

Family

ID=46889414

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280039854.XA Pending CN103732202A (zh) 2011-07-26 2012-07-26 用于眼部给药的两部分制剂系统
CN201810562582.0A Pending CN108514547A (zh) 2011-07-26 2012-07-26 用于眼部给药的两部分制剂系统

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810562582.0A Pending CN108514547A (zh) 2011-07-26 2012-07-26 用于眼部给药的两部分制剂系统

Country Status (8)

Country Link
US (4) US20130029919A1 (https=)
EP (2) EP3329896A1 (https=)
JP (2) JP6271423B2 (https=)
KR (1) KR102031997B1 (https=)
CN (2) CN103732202A (https=)
AU (4) AU2012286857B2 (https=)
CA (1) CA2843267C (https=)
WO (1) WO2013016494A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999543A (zh) * 2014-10-17 2017-08-01 汇恩斯株式会社 包含环孢霉素和海藻糖的眼用组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014212275B2 (en) 2013-02-01 2018-09-06 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
DK2950648T3 (da) 2013-02-01 2019-12-02 Ocuphire Pharma Inc Vandige oftalmiske opløsninger af phentolamin og medicinske anvendelser deraf
US20170112936A1 (en) * 2014-05-23 2017-04-27 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
KR101740869B1 (ko) 2016-12-16 2017-05-29 국제약품 주식회사 설파살라진 및 히알루론산을 함유하는 안약 조성물
CN108707212B (zh) * 2018-05-02 2020-01-07 上海交通大学 一种水溶性共轭聚合物纳米粒子的可控制备方法
EP3866790A4 (en) 2018-10-15 2022-08-03 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES
CA3116589A1 (en) 2018-10-26 2020-04-30 Ocuphire Pharma, Inc. Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409904A (en) * 1984-11-13 1995-04-25 Alcon Laboratories, Inc. Hyaluronic acid compositions and methods
CN1185953A (zh) * 1996-12-27 1998-07-01 刘伟中 富氧舒眼液及其生产工艺
CN1249687A (zh) * 1997-03-17 2000-04-05 诺瓦提斯公司 用于降低眼高压的组合物和方法
CN1265879A (zh) * 1998-12-17 2000-09-13 莱雅公司 基于脱水山梨糖醇脂肪酸酯的毫微乳液及其应用
WO2001019364A1 (en) * 1999-09-16 2001-03-22 Horn Gerald D A method for optimizing pupil size using alpha antagonist
US20060257388A1 (en) * 2005-05-13 2006-11-16 Julius Knowles Drug delivery systems for stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US20080004310A1 (en) * 2006-06-19 2008-01-03 Applied Pharmacy Services, Inc. Lyophilized pharmaceutical composition
CN101528217A (zh) * 2006-10-18 2009-09-09 博士伦公司 包含二甘氨酸的眼用组合物
CN101677941A (zh) * 2007-05-10 2010-03-24 默克专利有限公司 含水药物制剂
CN101820917A (zh) * 2007-10-08 2010-09-01 佛维雅制药股份有限公司 水性眼科配制剂
CN101874228A (zh) * 2007-09-26 2010-10-27 因特瑞有限公司 时间指示装置
CN101918019A (zh) * 2007-10-08 2010-12-15 卢克斯生物科技公司 包含钙调神经磷酸酶抑制剂或mTOR抑制剂的眼科组合物
CN101990437A (zh) * 2008-01-04 2011-03-23 阿尔康药品有限公司 稳定的环孢菌素水性组合物
CN102028697A (zh) * 2009-09-27 2011-04-27 上海信谊药厂有限公司 含非离子表面活性剂的拉坦前列素滴眼液及制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879304A (en) 1987-05-01 1989-11-07 Angelini Pharmaceuticals Ltd. Ophthalmic compositions and process for preparing
JPS6452722A (en) * 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
JPH0558906A (ja) * 1991-09-06 1993-03-09 Sankyo Co Ltd シクロスポリン点眼製剤
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
ID26032A (id) 1998-04-29 2000-11-16 Novartis Ag Metode dan komposisi untuk menyetabilkan komposisi asetilkolin
AU1735001A (en) * 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
US6902335B2 (en) * 2003-05-08 2005-06-07 R.P. Scherer Technologies, Inc. Hand held dispensing and application apparatus
US9561178B2 (en) 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US20080095754A1 (en) 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
PL391002A1 (pl) 2007-08-09 2010-10-25 Senju Pharmaceutical Co, Ltd Dwuskładnikowe krople do oczu zawierające pirenoksynę
US20090221984A1 (en) * 2008-03-03 2009-09-03 Akram Girgis Method and apparatus for providing therapeutically effective dosage formulations of lidocaine with and without epinephrine
HUE024146T2 (en) 2008-05-07 2016-02-29 Univ California Medical filling and enrichment of eye surface lubrication
US20110178147A1 (en) * 2009-10-20 2011-07-21 Allergan, Inc. Compositions and methods for controlling pupil dilation
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409904A (en) * 1984-11-13 1995-04-25 Alcon Laboratories, Inc. Hyaluronic acid compositions and methods
CN1185953A (zh) * 1996-12-27 1998-07-01 刘伟中 富氧舒眼液及其生产工艺
CN1249687A (zh) * 1997-03-17 2000-04-05 诺瓦提斯公司 用于降低眼高压的组合物和方法
CN1265879A (zh) * 1998-12-17 2000-09-13 莱雅公司 基于脱水山梨糖醇脂肪酸酯的毫微乳液及其应用
WO2001019364A1 (en) * 1999-09-16 2001-03-22 Horn Gerald D A method for optimizing pupil size using alpha antagonist
US20060257388A1 (en) * 2005-05-13 2006-11-16 Julius Knowles Drug delivery systems for stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US20080004310A1 (en) * 2006-06-19 2008-01-03 Applied Pharmacy Services, Inc. Lyophilized pharmaceutical composition
CN101528217A (zh) * 2006-10-18 2009-09-09 博士伦公司 包含二甘氨酸的眼用组合物
CN101677941A (zh) * 2007-05-10 2010-03-24 默克专利有限公司 含水药物制剂
CN101874228A (zh) * 2007-09-26 2010-10-27 因特瑞有限公司 时间指示装置
CN101820917A (zh) * 2007-10-08 2010-09-01 佛维雅制药股份有限公司 水性眼科配制剂
CN101918019A (zh) * 2007-10-08 2010-12-15 卢克斯生物科技公司 包含钙调神经磷酸酶抑制剂或mTOR抑制剂的眼科组合物
CN101990437A (zh) * 2008-01-04 2011-03-23 阿尔康药品有限公司 稳定的环孢菌素水性组合物
CN102028697A (zh) * 2009-09-27 2011-04-27 上海信谊药厂有限公司 含非离子表面活性剂的拉坦前列素滴眼液及制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999543A (zh) * 2014-10-17 2017-08-01 汇恩斯株式会社 包含环孢霉素和海藻糖的眼用组合物
CN106999543B (zh) * 2014-10-17 2021-01-05 汇恩斯株式会社 包含环孢霉素和海藻糖的眼用组合物

Also Published As

Publication number Publication date
JP2018062521A (ja) 2018-04-19
JP6271423B2 (ja) 2018-01-31
KR20140054125A (ko) 2014-05-08
US20130029919A1 (en) 2013-01-31
CA2843267C (en) 2020-08-18
AU2020267145A1 (en) 2020-12-03
WO2013016494A1 (en) 2013-01-31
EP3329896A1 (en) 2018-06-06
KR102031997B1 (ko) 2019-10-14
US20160235666A1 (en) 2016-08-18
US9616017B2 (en) 2017-04-11
AU2012286857B2 (en) 2017-07-27
US20190290722A1 (en) 2019-09-26
CN108514547A (zh) 2018-09-11
AU2012286857A1 (en) 2014-02-20
CA2843267A1 (en) 2013-01-31
AU2019203069A1 (en) 2019-05-23
EP2736475A1 (en) 2014-06-04
JP2014531401A (ja) 2014-11-27
US10314887B2 (en) 2019-06-11
AU2017251720A1 (en) 2017-11-09
US20170209532A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
CN103732202A (zh) 用于眼部给药的两部分制剂系统
JP6440893B1 (ja) 半フッ素化アルカン組成物
CN102341125B (zh) 包含头孢噻呋和酮洛芬或头孢噻呋和苯甲醇的配制剂
WO2015182647A1 (ja) 抗菌水
WO2007020085A2 (en) Compositions containing taxane derivatives for intravenous injection
KR101843613B1 (ko) 약제학적 페메트렉시드 액제
WO2014204952A1 (en) Stable bromfenac solution
US20140364379A1 (en) Two part formulation system for ophthalmic delivery
WO2014120293A1 (en) Ophthalmic formulations
KR20250065723A (ko) 멸균 처리한 헤테로시클리덴아세트아미드 유도체 함유 현탁액
WO2023148763A1 (en) Injectable pharmaceutical compositions of azole antifungal agents
CN101636163B (zh) 含有吡诺克辛的混悬型水性液体制剂
Kumar et al. Parenteral Suspensions: Stability Enhancing Liquid Dosage Forms
WO2024127418A1 (en) Injectable compositions of posaconazole
AU2024262981A1 (en) Injectable compositions of metolazone
HK40110131A (en) Semifluorinated alkane compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140416

RJ01 Rejection of invention patent application after publication